PRINCIPAL FINANCIAL GROUP INC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$34,421
+12.8%
57,793
+9.0%
0.00%
Q2 2023$30,505
-96.3%
53,034
-95.4%
0.00%
-100.0%
Q1 2023$816,017
-69.3%
1,160,930
-1.4%
0.00%
-50.0%
Q4 2022$2,661,821
-29.2%
1,177,797
+0.3%
0.00%
-33.3%
Q3 2022$3,759,000
-15.4%
1,174,585
+0.5%
0.00%0.0%
Q2 2022$4,443,000
-34.4%
1,169,245
-6.9%
0.00%
-25.0%
Q1 2022$6,768,000
-60.3%
1,255,601
-0.5%
0.00%
-60.0%
Q4 2021$17,047,000
+41.3%
1,261,799
+87.8%
0.01%
+25.0%
Q3 2021$12,068,000
+4.1%
671,938
-0.6%
0.01%
+14.3%
Q2 2021$11,594,000
-12.9%
675,658
+1.5%
0.01%
-22.2%
Q1 2021$13,315,000
+37.9%
665,756
+17.2%
0.01%
+28.6%
Q4 2020$9,657,000
+2.6%
568,053
+0.1%
0.01%
-12.5%
Q3 2020$9,414,000
-30.4%
567,483
-2.9%
0.01%
-33.3%
Q2 2020$13,532,000
+36.1%
584,302
+4.9%
0.01%
+9.1%
Q1 2020$9,941,000
-40.4%
556,906
-27.9%
0.01%
-21.4%
Q4 2019$16,679,000
+236.3%
772,730
+183.8%
0.01%
+250.0%
Q3 2019$4,959,000
-50.1%
272,264
-2.5%
0.00%
-55.6%
Q2 2019$9,937,000
+2.0%
279,282
-3.7%
0.01%0.0%
Q1 2019$9,741,000
+2.8%
289,912
+0.6%
0.01%
-10.0%
Q4 2018$9,474,000
-45.6%
288,227
+0.9%
0.01%
-33.3%
Q3 2018$17,410,000
+44.8%
285,590
+16.0%
0.02%
+36.4%
Q2 2018$12,022,000
-69.1%
246,201
-32.8%
0.01%
-70.3%
Q1 2018$38,951,000
-53.6%
366,564
-73.9%
0.04%
-51.9%
Q4 2017$83,981,000
+140.0%
1,406,257
-3.5%
0.08%
+126.5%
Q3 2017$34,992,000
+17.0%
1,458,007
-4.7%
0.03%
+13.3%
Q2 2017$29,910,000
-16.7%
1,529,950
+0.0%
0.03%
-30.2%
Q1 2017$35,907,000
+96.5%
1,529,892
+2.7%
0.04%
+87.0%
Q4 2016$18,271,000
-19.9%
1,489,045
+12.1%
0.02%
-23.3%
Q3 2016$22,817,000
+25.6%
1,328,083
+4.0%
0.03%
+20.0%
Q2 2016$18,165,000
+5.3%
1,276,593
+1.8%
0.02%0.0%
Q1 2016$17,248,000
-15.3%
1,254,366
+3.8%
0.02%
-16.7%
Q4 2015$20,359,000
+61.3%
1,208,204
+4.9%
0.03%
+50.0%
Q3 2015$12,623,000
-9.6%
1,151,694
+3.2%
0.02%
-4.8%
Q2 2015$13,963,000
+336.3%
1,116,130
+283.6%
0.02%
+320.0%
Q1 2015$3,200,000
-28.1%
290,949
+1.4%
0.01%
-28.6%
Q4 2014$4,449,000
+20.2%
287,042
-6.4%
0.01%
+16.7%
Q3 2014$3,700,000
-4.3%
306,530
+1.7%
0.01%0.0%
Q2 2014$3,865,000
+2.7%
301,481
-2.9%
0.01%
-14.3%
Q1 2014$3,764,000
+1202.4%
310,543
+1120.7%
0.01%
+600.0%
Q4 2013$289,000
-10.5%
25,440
-17.7%
0.00%0.0%
Q3 2013$323,000
-22.2%
30,930
-13.8%
0.00%0.0%
Q2 2013$415,00035,9020.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q3 2017
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders